A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.